STRATA Skin Sciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that STRATA Skin Sciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $278.5K | Mar 5, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.70M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $33.56M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $33.36M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $36.16M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $29.98M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $23.09M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $31.59M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $29.86M | Mar 17, 2020 |
| FY2018 | Sep 30, 2018 | $7.73M | Oct 30, 2019 |
| FY2018 | Jun 30, 2018 | $7.39M | Oct 30, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $31.45M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $30.71M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $18.50M | Mar 13, 2017 |
| FY2015 | Dec 31, 2014 | $915.0K | Mar 15, 2016 |
| FY2014 | Dec 31, 2013 | $536.0K | Mar 30, 2015 |
| FY2014 | Dec 31, 2012 | $278.0K | Mar 30, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.88M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.22M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $18.46M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $21.77M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $19.85M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $14.13M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $20.27M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $17.12M | Mar 17, 2020 |
| FY2018 | Sep 30, 2018 | $4.63M | Oct 30, 2019 |
| FY2018 | Jun 30, 2018 | $3.84M | Oct 30, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.26M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | ($2.58M) | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | ($2.12M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($10.09M) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | ($2.07M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | ($91.0K) | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | ($3.37M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($10.83M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($5.55M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.71M) | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.70M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | ($2.31M) | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | ($1.71M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($9.26M) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | ($1.61M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | ($478.0K) | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | ($2.89M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($8.60M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($4.65M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.40M) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $421.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $883.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.32M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.03M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.43M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.27M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $1.00M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.07M | Mar 17, 2020 |
| FY2018 | Sep 30, 2018 | $224.0K | Oct 30, 2019 |
| FY2018 | Jun 30, 2018 | $269.0K | Oct 30, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $9.19M | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $3.14M | Mar 15, 2016 |
| FY2014 | Dec 31, 2013 | $15.54M | Mar 30, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.79M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $188.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($519.0K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($924.0K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.51M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.10M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $2.23M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.90M | Mar 17, 2020 |
| FY2018 | Sep 30, 2018 | $1.80M | Oct 30, 2019 |
| FY2018 | Jun 30, 2018 | ($68.0K) | Oct 30, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.64M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.02M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.74M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.65M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.16M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $115.0K | Mar 25, 2021 |
| FY2014 | Dec 31, 2014 | $0 | Mar 30, 2015 |
| FY2014 | Dec 31, 2013 | $5.19M | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $6.16M | Mar 17, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.52M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $29.49M | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $33.03M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $34.93M | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | $39.38M | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $38.76M | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | $39.23M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $42.02M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $52.27M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $46.59M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.61M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $28.96M | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $30.05M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $29.96M | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | $29.98M | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $29.25M | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | $29.79M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $29.33M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $30.44M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $21.18M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.91M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $532.0K | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $2.98M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.97M | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | $9.40M | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $9.51M | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | $9.43M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $12.69M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $21.83M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $25.41M | Mar 28, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.43M | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | $1.43M | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | $1.43M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.43M | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | $5.70M | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | $5.70M | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | $5.70M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.52M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $8.80M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $8.80M | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($254.41M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | ($252.84M) | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | ($250.27M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($248.14M) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | ($243.59M) | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | ($241.52M) | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | ($241.42M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($238.06M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($227.23M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($221.68M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.91M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.26M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.78M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $5.43M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $12.59M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.60M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $8.13M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $16.49M | Mar 17, 2020 |
| FY2018 | Sep 30, 2018 | $15.89M | Oct 30, 2019 |
| FY2018 | Jun 30, 2018 | $14.45M | Oct 30, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.35M | Mar 26, 2026 |
| FY2024 | Dec 31, 2024 | $15.00M | Mar 28, 2025 |
| FY2023 | Dec 31, 2023 | $15.00M | Mar 28, 2024 |
| FY2022 | Dec 31, 2022 | $8.00M | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $8.00M | Mar 21, 2022 |
| FY2020 | Dec 31, 2020 | $2.53M | Mar 25, 2021 |
| FY2016 | Dec 31, 2016 | $40.73M | Mar 13, 2017 |
| FY2015 | Dec 31, 2015 | $40.99M | Mar 15, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 26, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 26, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 26, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.89M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 4.17M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 3.51M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 34.72M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 34.36M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 33.80M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | 32.93M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 29.94M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 4.30M | Oct 30, 2019 |
| FY2017 | Dec 31, 2016 | 2.17M | Apr 2, 2018 |